Ihps associated with maternal erythromycin intake or neonatal erythromycin exposure in early life?

ihps associated with maternal erythromycin intake or neonatal erythromycin exposure in early life?

Infantile hypertrophic pyloric stenosis (IHPS) is a condition characterized by the hypertrophy and thickening of the pylorus, which is the muscular valve that controls the passage of food from the stomach to the small intestine. It typically presents in the first few weeks of life and leads to projectile vomiting and feeding difficulties in affected infants.

Research has shown an association between maternal erythromycin intake during pregnancy and an increased risk of IHPS in infants. Erythromycin is an antibiotic that can be prescribed to pregnant women for various reasons, such as treating infections. The exact mechanism by which erythromycin increases the risk of IHPS is not fully understood, but it is believed to be related to its effect on the motility and muscle function of the pylorus in the developing fetus.

Additionally, neonatal exposure to erythromycin in early life has also been associated with an increased risk of IHPS. Erythromycin is sometimes given to newborns for the prevention or treatment of certain infections. The exposure to erythromycin shortly after birth can affect the muscular development and function of the pylorus, contributing to the development of IHPS.

It’s important to note that the association between erythromycin and IHPS is considered to be relatively rare. The absolute risk of developing IHPS after erythromycin exposure is low, but it is still important for healthcare providers to weigh the potential risks and benefits when considering the use of erythromycin in pregnant women or newborns.

If you have concerns about IHPS or the use of erythromycin, it is recommended to consult with a healthcare provider who can provide personalized advice and guidance based on your specific situation.